Rapid color-based accurate diagnosis for urinary tract infections
Diagopreutic, founded in 2022, provides advanced and affordable diagnostics solutions for infection control. The company is developing innovative solutions for faster and reliable outcomes for hospitals and primary health centers, aiming to combat Antimicrobial Resistance (AMR). AMR-related deaths are projected to increase from 700,000 to 10 million annually by 2050. The core team has combined 30+ years of experience in R&D and fundraising. Diagopreutic plans to achieve its objectives by converting leads from hospital lab tests, rolling out products through partner organizations, and utilizing online stores.
10 lakhs (DST NIDHI PRAYAS), May 2022 - May 2023. 10 lakhs (SISF). 10 lakhs (Goa SPC), April 2024 - April 2025. Big-50 lakhs.
The intellectual property portfolio includes a granted Indian patent for rapid bacterial identification and antibiotic sensitivity, a pending patent for a surface hygiene assessment electronic tool, and design registration for a hygiene assessment tool. It also includes a copyright for software used for semiquantification.
The company has achieved CDSCO product approval for a manufacturing license for their UTI kit (December 2025). They have also won several awards, including 2nd Prize in the Diagnostic Category at the International Knowledge Millennium Conference (IKMC) 2023 (Rs. 75,000/-), 1st Prize in the Start-Up Biochallenge organized by BITS Pilani KK Birla Goa Campus (Rs. 15,000/-), 1st Prize in Amazing Imaging Edition 2 organized by VNIR Biotechnologies Pvt Ltd (Rs. 15,000/-), and 2nd Prize Ideathon Award in Healthcare Technologies (Rs. 10,000/-) from GSIC (December 2021).
A team of 9 with 22+ years of combined experience in cutting-edge research and teaching, led by a CEO with a PhD from Ludwig Maximilian University, Munich, and a CDO who is an ex. assistant professor.
Director and CEO
Director and CDO
